Nature Cancer

🌻Check out our June issue ! ✅Metastatic dissemination in CRC ✅Immunotherapy in GBM ✅BH3 mimetics sensitization in AML ✅ctDNA and PSA to monitor prostate cancer ✅Methylation-based CNS tumor classification and more nature.com/natcancer/volu…

🌟Online today A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages nature.com/articles/s4301…

Great week for the Bruno lab for publications. Check out our new commentary on #TLS in @NatureCancer @PittTweet @UPMCHillmanCC nature.com/articles/s4301…

In first-in-human phase 1 NOA16 trial, Platten and colleagues report the long-term clinical and immunological follow-up outcomes of a vaccine targeting mutant IDH1 in persons with astrocytoma. @Platten_lab nature.com/articles/s4301…

Zemp at al. found GPNMB as a targetable antigen for MiT/TFE-family fusion-driven soft-part sarcoma and translocation RCC and tested GPNMB-directed CAR T cell therapy in preclinical models and in first-in-human trial. Read the N&Vs: nature.com/articles/s4301… nature.com/articles/s4301…

🚨Check out our last release Bayik and colleagues show that inhibition of GABBR signaling extends survival in female glioblastoma models, highlighting the potential for sex-specific cancer treatments and the unique immune landscape shaped by GABA nature.com/articles/s4301…

⭐️Online now Iron level and ferroptosis impair antitumor efficacy of CAR-T cells. by Dongrui Wang, Yongxian Hu, Pengxu Qian, He Huang & colleagues nature.com/articles/s4301…

📢Online now! @MoritzGerstung, Felix Sahm & co developed an AI algorithm that leverages H&E slides to classify central nervous system tumors into methylation-based subtypes reducing turnaround time to 12 min in prospective evaluation. nature.com/articles/s4301…

⭐️Now online In a large cohort of patients with ICB-treated glioblastoma, Catherine J. Wu & colleagues show that baseline mesenchymal transcriptional state predicts therapy response, and transition to non-mesenchymal state results in acquired resistance. nature.com/articles/s4301…

🔥Bacterial engineering for cancer therapy 🆙 @NatureCancer ☑Engineered bacteria as living drug delivery systems for cytotoxics & immunotherapeutics 🎯Payload selection, controlled release & safety optimization are key for clinical translation 🎙Dr. Noah Chen @arpaialab @OncoAlert @Larvol nature.com/articles/s4301…

Calling all scientists working on bedside omics, biomarkers, therapeutics, & precision health-related topics. Share your latest findings w/ global experts + @NatureMedicine @NatureCancer & @CommsMedicine editors at our inaugural Flagship. Submit by 6/30> go.nature.com/4uTnDww

Delighted to share our @NatureCancer paper, out today, on determinants of ICB response in GBM (link in 🧵) With bulk and single-nucleus genomic profiling of 181 ICB-treated tumors, we found that tumor RNA subtype (and not TMB!) predicts survival and shapes acquired resistance.

Excited to share some of my PhD work out today in @NatureCancer! Integrating bulk and single-nucleus genomic approaches, we identify distinct determinants of survival and acquired resistance to ICB versus standard chemoradiation in glioblastoma. #Abs1" target="_blank" rel="nofollow noopener">nature.com/articles/s4301…

🍓☀️Check out our May Issue, now live! Including: ☑️Oncolytic virus and cytokine-based gene therapies ☑️Myeloid plasticity, part of our Series on Tumor Heterogeneity and Plasticity ☑️DeepFAN, a model for human-AI collaboration and more! nature.com/natcancer/volu…

🚨New in Nature Cancer Kimberly J. Perez and colleague show that adding the VDR agonist paricalcitol to gemcitabine + nab‑paclitaxel in metastatic pancreatic cancer is feasible and and provides early indications of TME remodeling @DanaFarber @Cancer nature.com/articles/s4301…

Out today! CD300ld, upregulated in pathologically activated neutrophils, mediates contact-dependent suppression of cytotoxic CD8+ T cells by binding to phosphatidylserine, inhibiting antitumor immune responses and revealing a targetable checkpoint pathway nature.com/articles/s4301…

🌟Online now! The Review on myeloid cell plasticity in cancer therapy by Dmitry Gabrilovich & colleagues @GabrilovichLab 🔗nature.com/articles/s4301… Check out the rest of the Series on Tumor Heterogeneity and Plasticity here: nature.com/collections/gf…

⭐Out today! Read the phase I clinical trial on neoantigen DNA vaccine for patients with glioblastoma nature.com/articles/s4301…

⭐️Check out the Perspective on cellular neighborhoods in cancer by @LichunMa, @KaiTanLab1 & co 🔗nature.com/articles/s4301… Part of our Series on Tumor Heterogeneity and Plasticity: nature.com/collections/gf…

A phase 1 clinical trial now published @naturecancer 'Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors' ✒️By Hilde De Winter & colleagues 🔗nature.com/articles/s4301…